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Abstract
Background: In animal experiments persistent organic pollutants (POPs) cause hepatosteatosis. In epidemiological
studies POPs have positive associations with serum markers of nonalcoholic fatty liver disease (NAFLD) and together
with obesity synergistic association with insulin resistance. Because insulin resistance and obesity are critical in
NAFLD pathogenesis, we investigated the association of serum pollutant levels with liver histology and alanine
aminotransferase (ALT) in morbidly obese.
Methods: Liver biopsies were from 161 participants of the Kuopio Obesity Surgery Study (KOBS) who underwent
bariatric surgery 2005–2011. Liver histology was categorized as normal, steatosis and non-alcoholic steatohepatitis
(NASH). Liver phenotype at baseline and ALT at baseline and 12 months post-surgery were correlated to serum POP
concentrations at respective time points. As lipophilic POPs concentrate to smaller fat volume during weight loss,
serum levels before and 12 months after bariatric surgery were compared.
Results: Baseline serum concentration of PCB-118, β-HCH and several PFAAs had an inverse association with lobular
inflammation possibly due to changes in bile acid metabolism. ALT had negative associations with many POPs at
baseline that turned positive at 12 months after major clinical improvements. There was an interaction between some
POPs and sex at 12 months, and in stratified data positive associations were observed mainly in females but not in males.
Conclusions: We found a negative association between serum concentrations of PCB-118, β-HCH and several PFAAs
with lobular inflammation at baseline. Positive POPs-ATL associations at 12 months among women suggest that
increased POP concentrations may decrease the degree of liver recovery.
Keywords: Persistent organic pollutants, Perfluorinated alkyl acids, Non-alcoholic fatty liver disease, Obesity,
Bariatric surgery
Background
Non-alcoholic fatty liver disease (NAFLD) is rapidly be-
coming the most common cause of liver disease and it is
estimated that NAFLD affects 20–30 % of the population
in the West [1]. Within the liver, NAFLD can progress
to non-alcoholic steatohepatitis (NASH) and liver cir-
rhosis, and ultimately to liver failure [2]. Furthermore,
patients with NAFLD exhibit increased risk of develop-
ing type 2 diabetes (T2D), cardiovascular disease (CVD),
chronic kidney disease, and certain malignancies [3]. In-
sulin resistance [4] and obesity [5] are two important el-
ements in the pathogenesis of NAFLD. Both increase
the inflow of free fatty acids (FFAs) to the liver from
subcutaneous and visceral fat and contribute to “de
novo” intrahepatic synthesis of triglycerides [6]. In
humans healthy diet [7], weight loss and increased
physical activity [8] improve NAFLD. Bariatric sur-
gery has been shown to improve components of the
metabolic syndrome, with a dramatic reduction in
hepatic steatosis and an improvement in the NAFLD
stage [9].
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Persistent organic pollutants (POPs) are heterogeneous
group of chemicals harmful to humans. In Finland the
main exposure routes are the consumption of fatty fish
[10] and house dust [11, 12]. Production and use of
many POPs has been banned by international treaties.
Decreasing time trends of exposure have been observed
in the Nordic Countries e.g. for polychlorinated biphenyls
(PCBs) and organochlorine pesticides (OCPs) since 1960’s
and 1970’s [13], for polybrominated diphenylethers (PBDEs)
since 1990’s [14] and for perfluorinated alkyl acids (PFAAs)
since 2000’s [15]. Due to their lipophilicity POP are stored
in humans primarily in adipose tissue and also in the liver
[16], but animal and some human data indicate that dioxin-
like compounds are also selectively sequestrated to liver
[16, 17]. Contrary to other POPs, PFAAs are not lipophilic
and they have been shown to bind to proteins in blood and
especially in the liver of animals [18] and to various protein
rich tissues also in humans [19].
In rats single high oral dose of certain PCBs [20] and
OCPs [21] increases deposition of triglycerides to liver.
These effects may also depend on the diet. For example,
in rats POP contaminated salmon oil (but not deconta-
minated) caused hepatosteatosis [22], while in mice POP
contaminated whale meat did not [23]. PCBs have also
been proposed to act as a “second hit” driving steatosis
to NASH in mice exposed to high fat diet [24]. Regard-
ing PFAAs, hepotomegaly is commonly observed as a
sign of hepatotoxicity in rodents and nonhuman pri-
mates [18].
In humans serum levels of certain lipophilic POPs have
been associated with NAFLD related conditions (e.g. T2D
and obesity). Regarding T2D, reviews of cross-sectional
studies suggest/support a positive association for certain
organochlorine POPs, such as trans-nonachlor, dichlorodi-
phenyldichloroethylene (p,p′-DDE), and PCBs [25, 26]. A
recent meta-analysis of seven existing prospective studies
indicated towards the temporal precedence for hexachloro-
benzene (HCB) and total PCBs, but the data was insuffi-
cient to establish causality [27]. Regarding obesity, a
current review concluded that OC pesticides (especially
p,p′-DDE) tend to be positively associated or not associ-
ated with obesity, but PCBs have also shown inverse asso-
ciations in many studies [28]. Two prospective studies
have been conducted. One study among young adults ob-
served that p,p′-DDE and PCBs with ≥7 chlorines had
inverted U-shaped association with increased body mass
index in 18 years follow-up [29]. In another study among
elderly adults low-dose exposure to less chlorinated PCBs,
p,p′-DDE, and dioxins were associated with the develop-
ment of abdominal obesity in 5 years follow-up [30]. In
addition, POPs and obesity together have a synergistic as-
sociation with T2D or insulin resistance [31, 32]. Regard-
ing NAFLD itself, an increase in serum PCB levels was
associated with alanine aminotransferase (ALT) elevation,
a proxy marker of NAFLD among general adult popu-
lation (NHANES 2003–2004) [33]. To support an
interaction with insulin resistance there was a positive
association between PFOA and ALT and γ-GT espe-
cially in obese and insulin resistant individuals with or
without metabolic syndrome in NHANES 1999–2000
and 2003–2004 [34]. Experimental studies suggest that
POPs may activate nuclear receptors including aryl hydro-
carbon receptor (AhR), pregnane X receptor (PXR) and
constitutive androstane receptor (CAR). Through these
receptors POPs may induce the regulation of genes in-
volved in the inflammatory pathway, mitochondrial func-
tion, lipid oxidation, and lipogenesis, thereby contributing
to development of insulin resistance and obesity [22, 28].
Based on the proposed interaction of obesity and insu-
lin resistance with POP exposure, morbidly obese repre-
sent a population where the association between POPs
and NAFLD is most likely seen if that exists. In addition,
because plasma levels of lipophilic POPs increase after diet
induced weight loss [35, 36] or bariatric surgery [35, 37] as
they concentrate to a smaller adipose tissue volume, the
impact of increased POP concentrations after weight loss
on the improvement of liver function is of interest. Only
one study has explored the metabolic associations of POP
levels before and after bariatric surgery. Pre-surgery serum
POP levels had significant positive partial correlations
(adjusted for age and sex) with liver dysfunction markers
(ALT, AST and γ-GT). Using similar test increased post-
surgery POP concentrations were associated with a dimin-
ished improvement of liver related parameters [37].
Notably, none of the studies investigating the rela-
tionship between POPs and liver disease have relied
on liver biopsy, the golden standard for the evaluation
of NAFLD and NASH [38]. In this study we investi-
gated the association of serum levels of several POPs
with detailed liver histology and metabolic parameters
in morbidly obese patients. Furthermore, levels before




Altogether 161 subjects (47.6 ± 8.4 years, BMI 44.6 ±
5.7 kg/m2) were selected from an ongoing Kuopio Obes-
ity Surgery Study (KOBS) including all subjects undergo-
ing bariatric surgery at the Kuopio University Hospital
[39]. Recruitment and surgery of study subjects took place
during the years 2005–2011. Selection criteria for the study
were according to Finnish Current Care Guidelines that
are based on the National Institutes of Health Consensus
Development Conference Statement from 1991 [40]. De-
tailed criteria were 1) BMI >40 kg/m2, 2) BMI 35–40 kg/
m2 and comorbidity or its risk factor, such as T2D, hyper-
tension, sleep apnea, osteoarthritis of weight bearing joints
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or polycystic ovarian syndrome, 3) failure of dietary and
drug treatments, and 4) no other contraindication for oper-
ation. Over 90 % of the eligible recruited individuals partic-
ipated. Alcohol consumption of ≤2 doses per day was
applied as study inclusion criteria. All participants were on
a very low calorie diet for 8 weeks before the surgery (800–
1000 kcal/day) during which 5–10 kg weight loss typically
occur for all patients. Weight loss in this cohort during the
1 year follow-up was 29.7 ± 11.9 kg (−24.6 %) [39]. In-
formed consent was obtained from each participant and
the study protocol was approved by the Ethics Committee
of Northern Savo Hospital District and was in accordance
with the Helsinki Declaration.
Clinical determinations and blood samples
During the week preceding the surgery every participant
had one-day visit including an interview on the history
of previous diseases, current drug treatment and an
evaluation of cardiovascular risk factors. On the morning
of surgery before preoperative preparation of patients fast-
ing blood samples were drawn after 12 h of fasting. Fasting
blood samples were also collected at 12 months after sur-
gery. The following analyses were carried out at baseline
and 1 year after the surgery: Plasma glucose by enzymatic
hexokinase photometric assay (Konelab Systems Reagents,
Thermo Fischer Scientific, Vantaa, Finland), serum in-
sulin by immunoassay (ADVIA Centaur Insulin IRI, no
02230141, Siemens Medical Solutions Diagnostics,
Tarrytown, NY), cholesterol and triglyceride levels
from the whole serum and from lipoprotein fractions
by automated enzymatic methods (Roche Diagnostics,
Mannheim, Germany) and plasma activities of ALT by
kinetic method according to the International Federation
of Clinical Chemistry (Roche Diagnostics Co).
Liver biopsies
Liver biopsies were obtained using Trucut needle
(Radiplast AB, Uppsala, Sweden) during elective gastric by-
pass operation (n = 161). Histological assessment of liver
was performed by one pathologist according to Brunt et al.
[41]. Steatosis was graded into 4 categories (<5, 5–33, 33–
66 % and >66 %); lobular inflammation into 4 categories
(no foci; <2, 2–4 and >4 per 200× field); ballooning was
staged from 0 to 2 and fibrosis from 0 to 4. Based on this
histological assessment a clear distinct liver phenotype
(normal, simple steatosis or NASH) could be determined
for 105 of these 161 patients (Table 1).
Chemical analysis of POPs and PFAAs
The method used for the analysis of 17 POPs and 13 PFAAs
from serum samples before and 12 months after bariatric
surgery has been described previously in detail [42]. POP
compounds measured were PCBs 118, 138, 153, 156,
170, and 180, pesticides HCB, β -hexachlorocyclohexane
(β-HCH), trans-nonachlor, p,p′-DDE, and brominated
diphenyl ethers BDE-47, BDE-99, BDE-153 and BDE-209.
PFAAs compounds were perfluorohexanesulfonic acid
(PFHxS), −octanosulfonic acid (PFOS), perfluorohexa-
noic acid (PFHxA), −octanoic acid (PFOA), −nonanoic
acid (PFNA), −decanoic acid (PFDA) and -undecanoic acid
(PFUnA). Also some other POPs and PFAAs were mea-
sured, but for those more than 70 % of samples had con-
centrations less than the limit of quantification (LOQ) and
are not treated further. To achieve better sensitivity espe-
cially for higher brominated PBDEs, the analysis of PBDEs
was performed with an Agilent 6890 gas chromatograph
equipped with a short column (J&W Scientific DB-5MS-
UI: 6 m, ID 0.18 mm, 0.18 μm) connected to Waters
Autospec Ultima high resolution mass spectrometer (GC-
HRMS). All concentrations of POPs are expressed as ng/g
of serum lipid whereas concentrations of PFAAs are
expressed as ng/ml of serum.
For POPs 2 blanks and 2 control samples (NIST
SRM1958) were included in each batch of samples
(n = 9). Measured concentrations of POPs in SRM1958
were 80–105 % of the certified/reference concentrations,
except for BDE-209 for which it was 72 %. Co-efficient of
variation (CV-%) from SRM 1958 (n = 18) was <3.6 % for
all compounds except for BDE-209 (16.7 %). For PFAAs
one blank and one in-house control serum sample were
included in each batch of samples (n = 4). PFAAs control
sample was prepared by spiking typical serum sample with
5.0 ng/ml of each PFAA analysed. CV-% from in-house
control serum (n = 4) ranged from 3.6 to 12.6 % depending
on the compound. During the POP/PFAAs analysis the la-
boratory participated to AMAP interlaboratory compari-
son rounds one and two of 2013 (Ring Test for Persistent
Organic Pollutants in human serum, National Institute of
Public Health, Quebec, Canada). For POPs laboratory re-
sults varied from 83 to 132 % and for PFAAs from 79 to
128 % of the assigned values depending on the com-
pound. LOQs were 2–15 pg/ml for POP and 0.08–
0.18 ng/ml for PFAAs.
Statistics
Kruskal-Wallis test for continuous variables and Chi-square
test for categorical variables were used to study the differ-
ence between clinical characteristics of patients at baseline
and at 12 months grouped by liver histology at baseline.
Percent changes in the concentrations of each PFAA and
POP compound from baseline to 12 months were calcu-
lated separately for each individual study subject who had
serum sample available at both time points. Percent
changes were calculated using concentrations in the ori-
ginal scale as 100*([conc. at 12 mo]-[conc. at baseline]/
[conc. at baseline]). For each compound mean, median, 5th
and 95th percentiles were calculated from percent changes
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Table 1 Clinical characteristics (mean ± SD) and liver histology by baseline liver phenotypea
Liver phenotype at baseline Normal Steatosis NASH
n = 42 n = 28 n = 35 pb
Sex (male/female) (% males) 15/27 (36) 7/21 (25) 14/21 (40) 0.446
Age (years) 48.2 ± 8.7 47.1 ± 8.7 47.3 ± 8.5 0.910
Weight 128.7 ± 20.4 124.0 ± 15.7 134.4 ± 23.9 0.265
Weight at 12 mo 102.0 ± 20.0 91.1 ± 6.2 98.9 ± 19.8 0.200
BMI (kg/m2) 44.0 ± 6.4 43.9 ± 3.9 44.8 ± 6.9 0.824
BMI at 12 mo (kg/m2) 35.2 ± 6.4 32.1 ± 2.4 33.3 ± 5.7 0.289
Fasting glucose (mmol/L) 6.0 ± 0.8 6.5 ± 2.2 7.0 ± 2.4 0.287
Fasting glucose at 12 mo (mmol/L) 5.4 ± 0.7 5.4 ± 0.7 5.3 ± 0.5 0.581
Fasting insulin (mU/L) 13.9 ± 6.7 18.7 ± 10.7 39.9 ± 59.1 <0.001
Fasting insulin at 12 mo (mU/L) 8.6 ± 5.2 7.8 ± 3.9 11.3 ± 11.9 0.958
Diabetes (no/yes) (%)c 32/10 (24) 18/10 (36) 18/16 (46) 0.105
Diabetes at 12 mo (no/yes) (%)d 30/1 (2.4) 17/0 (0) 24/0 (0) 0.511
Cholesterol (mg/l) 4.2 ± 0.9 4.0 ± 0.7 4.7 ± 1.2 0.040
Cholesterol at 12 mo (mg/l) 4.2 ± 0.8 4.2 ± 0.8 4.7 ± 0.9 0.264
Triglycerides (mg/l) 1.5 ± 0.6 1.6 ± 0.7 1.8 ± 0.9 0.076
Triglycerides at 12 mo (mg/l) 1.0 ± 0.4 1.0 ± 0.3 1.2 ± 0.4 0.222
Plasma adiponectin (μg/ml) 3.6 ± 2.0 4.0 ± 2.1 2.8 ± 1.7 0.084
Plasma adiponectin at 12 mo (μg/ml) 13.0 ± 37.2 16.2 ± 43.3 5.4 ± 3.4 0.205
ALT (U/L) 40.0 ± 25.5 43.8 ± 17.9 58.2 ± 31.4 0.042
ALT at 12 mo (U/L) 27.4 ± 12.9 24.9 ± 12.9 27.8 ± 25.3 0.626
Steatosisgrade (n) <0.001
<5 % 42 0 0
5–33 % 0 24 14
33–66 % 0 2 14
>66 % 0 2 7
Lobular Inflammation (n) <0.001
None 42 28 0
<2 foci per 200*field 0 0 25
2–4 foci per 200*field 0 0 10
Liver cell ballooning (n) <0.001
None 42 28 16
Few balloon cells (n) 0 0 15
Many cells/prominent ballooning 0 0 4
Fibrosis stage (n) <0.001
None 42 28 4
Perisinusoidal or periportal 0 0 26
Perisinusoidal and portan/periportal 0 0 22
Bridging fibrosis 0 0 12
Cirrhosis 0 0 1
aSelected clinical characteristics both at baseline and at 12 months and liver histology at baseline, all grouped by liver phenotype at baseline
bKruskal-Wallis test for continuous variables and Chi-square test for categorical variables
cPrevious doctor diagnosis of diabetes
dFasting glucose ≥7 at 12 months examination
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in individual study subjects. Differences in the serum POP
and PFAAs concentrations before and after bariatric sur-
gery were tested by Wilcoxon signed-rank test. These per-
cent changes in the serum contaminant concentrations
from baseline to 12 months are denoted with ΔPFAAs or
ΔPOPs.
Two different models were used to study the associ-
ations between liver histology at baseline and log-
transformed concentrations of POPs and PFAAs by
multinomial logistic regression. The first one was ad-
justed only for age and the second one was adjusted
for age, BMI, sex and fasting insulin (PFAAs also for
serum lipids). Stratification by sex was not performed
due to small number of cases in certain classes of
liver histology. BMI and serum insulin were added in
the models because they are central etiological factors
in NAFLD development.
Associations between log-transformed serum ALT
concentrations and log-transformed serum POPs (lipid
based) and PFAA concentrations (volume based) at
baseline and at 12 months were studied by linear re-
gression. At baseline models adjusted for age and models
adjusted for age, sex, BMI and fasting insulin were run.
Similar adjustments were performed at 12 months, but
BMI was replaced with weight change in kilos as weight
loss may be a better predictor of the chemical blood
concentrations than BMI at 12 months. Interaction
between sex and POPs was tested in separate models
at baseline and at 12 months by including sex*POPs
interaction term to fully adjusted models. Finally, fully
adjusted models between ALT and POPs stratified by
sex were also run.
To test the possibility of inflammation related pre-
surgery accumulation of POPs to liver and their post-
surgery release to serum, ΔPOP and ΔPFAAs were
calculated in different liver inflammation status groups.
Same tests with liver phenotype as grouping variable were
also performed. Differences in the percent changes be-
tween groups were tested by Kruskal-Wallis test.
In all statistical analysis results < LOQ were treated
as LOQ/2. In statistical analysis p-values <0.05 were
considered significant. All statistical tests were per-




Of the clinical parameters, the difference between study
groups (normal liver, simple steatosis and NASH) in
fasting insulin level at baseline was highly significant
mainly due to high insulin level in the NASH group
(Table 1). Significant differences were also observed for
fasting cholesterol and ALT at baseline.
Change in the levels of POPs and PFAAs from baseline to
12 months
Changes in the serum PFAAs concentrations in response
to surgery (ΔPFAAs) were generally very small (for me-
dian range −6.5–4.3 %) even though some changes were
significant in the Wilcoxon signed-rank test (Table 2). The
median of ΔPOPs for chlorinated lipid soluble POP were
significant (+39–+77 %) as expected, and for many com-
pounds 95th percentiles of ΔPOPs were around +200 %.
However, the behaviour of PBDEs was more variable: for
BDE47 and BDE209 median changes in serum concentra-
tions were small (12 and 11 %), but for BDE153 all
changes (mean, median, percentiles) were similar to those
for chlorinated POPs (Table 2).
POPs, PFAAs and liver histology at baseline
Associations between liver histology at baseline and log-
transformed concentrations of β-HCH and PCB118 are
shown in Table 3 (model adjusted for age, BMI, sex and
fasting insulin). β-HCH had significant negative association
with lobular inflammation (2–4 foci per 200x field, p =
0.022). For dioxin-like PCB-118 there was a negative asso-
ciation with NASH (p = 0.038), lobular inflammation (<2
foci per 200x field, p = 0.027, and 2–4 foci per 200x field, p
= 0.005), liver cell ballooning (few balloon cells p = 0.036)
and steatosis grade (33–66 %, p = 0.048). In addition, serum
concentrations of both β-HCH and PCB-118 generally de-
creased with impairment of all liver histology measures
(Table 3). Associations for β-HCH and PCB-118 in the
models adjusted only for age were mainly similar to those
in the fully adjusted model. However, in fully adjusted
model association of PCB-118 with diagnosis and steatosis-
grade was significant and the precision of the effect esti-
mates was increased as compared to models adjusted only
for age (Table 3 and Additional file 1: Table S1). Associa-
tions for other POPs were also mainly negative but
non-significant and are not tabulated.
Regarding PFAAs, in the fully adjusted model lobu-
lar inflammation (2–4 foci per 200x field) had significant
negative associations at baseline with PFOA (p = 0.027),
PFNA (p = 0.019), PFDA (p = 0.037), PFHxS (p = 0.018)
and sum of PFCA (p = 0.015) (Table 4). Respective associ-
ations in the models adjusted only for age were all non-
significant and the precision of the effect estimates was
decreased (Additional file 2: Table S2). No significant as-
sociations with other liver histology parameters at
baseline were observed.
POPs, PFAAs and serum ALT at baseline and at 12 months
Serum ALT was measured both at baseline and at
12 months. In the fully adjusted models at baseline
all chlorinated POPs had negative association with ALT
that reached statistical significance for β-HCH and
PCBs 153, 180 and 170. In the fully adjusted models
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at 12 months these associations turned positive and were
significant for PCB-118, PCB-156 and BDE-153 (Table 5).
In the models adjusted only for age associations were much
weaker at baseline, but only slightly weaker at 12 months
(Additional file 3: Table S3). At 12 months most POPs had
significant or nearly significant interaction with sex
(Table 5). In the analysis stratified by sex significant
or nearly significant associations between POPs and
ALT were most consistently observed among women
at 12 months (Additional file 4: Table S4).
Of the PFAAs, only PFHxA had significant positive
association (p = 0.011) with ALT at 12 months in the
model adjusted for age, fasting insulin and weight change
(results not shown).
Change in the levels of POPs and PFAAs and baseline
liver inflammation
Only BDE-153 had significant difference in the percent
change of concentrations from baseline to 12 months be-
tween different baseline liver phenotype groups (p = 0.009).
Discussion
This is the first study where serum concentrations of
POPs and PFAAs have been explored in relation to liver
phenotype (normal, simple steatosis, NASH) as deter-
mined by liver biopsy. Participants also had a follow-up
visit 12 months after the bariatric surgery where POP,
PFAAs and clinical parameters were re-determined fol-
lowing substantial weight loss. This study had two main
Table 2 Concentrations of PFAAs, OCPs, PCBs and PBDEs before and 12 months after bariatric surgery
Before surgery 12 months after surgery Changea
Mean Median (5th; 95th persentile) Mean Median (5th, 95th pers.) Mean Median (5th; 95th persentile.) p-value*
Compound nc ng/ml ng/ml nc ng/ml ng/ml % %
PFHxA 161 0.16 0.03 (0.03; 0.59) 118 0.16 0.03 (0.03, 0.56) 150b 0.00 (-92; 1108) 0.67
PFOA 161 2.63 2.56 (1.04; 4.66) 118 2.60 2.50 (1.00, 4.80) 0.1 -4.8 (-30; 33) 0.017
PFNA 161 0.96 0.83 (0.30; 2.19) 118 0.97 0.84 (0.29, 2.55) -1.2 -6.5 (-38; 46) 0.029
PFDA 161 0.27 0.23 (0.08; 0.60) 117 0.27 0.24 (0.08, 0.72) 4.4 -5.6 (-52; 92) 0.258
PFUnA 161 0.19 0.15 (0.02; 0.50) 118 0.18 0.13 (0.02, 0.54) 11 -3.3 (-77; 142) 0.042
PFHxS 161 1.42 1.18 (0.54; 2.90) 118 1.46 1.35 (0.50, 2.88) 9.9 4.3 (-50; 89) 0.332
PFOS 161 3.91 3.2 (0.89; 10.3) 118 3.91 3.32 (0.98, 8.76) 1.1 -3.4 (-32; 50) 0.038
sumPFCA 161 4.20 4.07 (1.8; 7.52) 118 4.17 3.94 (1.64, 7.77) -1.0 -6.1 (-29; 33) 0.003
sumPFSA 161 5.33 4.49 (1.75; 12.3) 118 5.37 4.82 (1.93, 11.3) 1.2 -2.1 (-31; 45) 0.222
Mean Median (5th; 95th pers.) Mean Median Mean Median (5th; 95th pers.) p-value*
Compound nc ng/g lipid ng/g lipid nc ng/g lipid ng/g lipid % %
HCB 149 12.8 10.9 (5.24; 23.3) 95 24.1 18.3 (7.31, 56.9) 113 77 (-12; 330) <0.001
BetaHCH 149 17.1 12.7 (2.60; 28.6) 95 19.2 17.6 (3.79, 41.3) 49 39 (-19; 147) <0.001
Transnonachlor 149 9.30 7.26 (1.59; 24.8) 95 14.5 10.9 (1.92, 41.6) 73 58 (-1.5; 190) <0.001
p,p′-DDE 149 151 100 (16.8; 504) 95 229 157 (23.3, 688) 73 67 (-2.0; 182) <0.001
PCB-118 149 13.3 10.0 (3.09; 33.3) 95 21.3 18.4 (4.82, 52.8) 68 62 (-8.6; 182) <0.001
PCB-153 149 75.4 62.8 (19.4; 193) 95 125 108 (28.4, 314) 73 61 (-0.10; 188) <0.001
PCB-138 149 39.8 32.2 (10.0; 103) 95 64.5 55.3 (14.0, 181) 71 65 (6.4; 176) <0.001
PCB-156 149 3.98 3.40 (0.91; 9.88) 95 6.64 6.15 (1.11, 15.5) 84 65 (-8.7; 254) <0.001
PCB-180 149 42.0 35.8 (11.2; 109) 95 69.2 62.0 (13.9, 164) 74 60 (-19; 196) <0.001
PCB-170 149 18.1 15.5 (4.74; 46.2) 95 29.7 28.0 (6.38, 65.4) 70 59 (-3.5; 182) <0.001
BDE-47 149 3.47 1.99 (1.11; 7.01) 95 4.48 2.17 (1.33, 12.2) 31 12 (-40; 183) 0.001
BDE-153 149 1.32 0.92 (0.31; 3.54) 95 2.40 1.53 (0.33, 8.82) 80 61 (-27; 241) <0.001
BDE-209 149 11.8 4.79 (1.60; 48.5) 95 15.4 5.02 (2.07, 62.7) 213 11 (-88; 1132) 0.436
sumPCB 149 193 163 (50.8; 482) 95 316 271 (72.2, 786) 72 62 (-3.6; 186) <0.001
sumBDE 149 16.6 8.94 (3.71; 59.5) 95 22.3 11.8 (4.83, 75.6) 115 21 (-79; 633) 0.036
*p-value from Wilcoxon signed-rank test
aMean, median, 5th and 95th persentile of serum PFAAs and POP concentration changes from baseline to 12 months were calculated from changes in individual
study subjects who had serum sample available at both time points (same n as in the 12 months after surgery column)
bA few extreme values rise the mean of percent change, but median remains 0 as substantial number of results were < LOQ both before and after surgery
cFor POPs n is smaller than for PFAAs both at baseline and at 12 months because for part of the study subjects lipid determination was not done at either
time point
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findings. First, there was an inverse association in the
serum concentration of dioxin-like PCB-118 with lobular
inflammation at baseline. β-HCH and several PFAAs
had similar associations, but less clear (Tables 3 and 4).
Second, ALT, as a marker of liver disease, had negative
association with POPs at baseline that turned positive at
12 months after major improvements in the liver func-
tion tests. For most POPs these associations were signifi-
cant or nearly significant at both time points (Table 5).
In addition, there was an interaction between some
POPs and sex at 12 months (Table 5), and stratified data
revealed positive associations between ALT and POPs in
females but not in males (Additional file 4: Table S4).
For POPs and PFAAs increased accumulation to liver
or increased excretion with disease progression could be
proposed as explanations to inverse associations. From
animal and human post mortem studies accumulation of
many dioxin-like compounds to liver is known to take
Table 3 Associations of liver histology with β-HCH and PCB118 at baselinea,b
β-HCH PCB-118
n Median (ng/g lipid) OR (95 % CI) p-value Median (ng/g lipid) OR (95 % CI) p-value
Diagnosis
Normal 38 13.4 Ref 15.2 Ref
Steatosis 28 12.8 3.03 (0.46; 20.10) 0.250 9.42 0.49 (0.07; 3.46) 0.473
NASH 31 11.9 0.33 (0.03; 3.73) 0.373 10.1 0.10 (0.01; 0.88) 0.038
Lobular Inflammation
None 92 13.2 Ref 11.1 Ref
<2 foci per 200x field 47 12.5 0.55 (0.11; 2.77) 0.468 9.14 0.16 (0.03; 0.81) 0.027
2–4 foci per 200x field 10 8.93 0.02 (<0.01; 0.59) 0.022 5.55 0.01 (<0.01; 0.26) 0.005
Liver cell ballooning
None 109 13.3 Ref 11.0 Ref
Few balloon cells 36 12.0 0.16 (0.02; 1.09) 0.061 9.23 0.17 (0.03; 0.89) 0.036
Many cells/prominent ballooning 4 8.65 0.35 (0.01; 23.27) 0.623 7.31 0.33 (0.00; 22.9) 0.606
Steatosisgrade
<5 % 50 13.1 Ref 12.6 Ref
5–33 % 59 13.5 1.09 (0.24; 4.83) 0.914 9.83 0.30 (0.06; 1.49) 0.141
33–66 % 23 11.9 0.19 (0.02; 2.15) 0.180 9.15 0.11 (0.01; 0.98) 0.048
>66 % 17 10.4 0.20 (0.02; 2.51) 0.213 9.14 0.14 (0.01; 1.44) 0.098
aResults reported only for β-HCH and PCB118 because other POPs had no significant associations
bConcentrations of β-HCH and PCB-118 (ng/g lipids) were log-transformed for the multinomial logistic regression analysis that was adjusted for age, BMI, sex and
fasting insulin
Table 4 Associations of lobular inflammation status with PFAAs at baselinea
Lobular Inflammation status
None (n = 96) <2 foci per 200x field (n = 53) 2–4 foci per 200x field (n = 11)
Compounda Median (ng/ml) Median (ng/ml) OR (95 % CI) p-value Median (ng/ml) OR (95 % CI) p-value
PFHxA 0.060 Ref 0.025 0.80 (0.38; 1.66) 0.547 0.083 0.77 (0.19; 3.03) 0.707
PFOA 2.61 Ref 2.61 0.71 (0.10; 5.18) 0.734 1.823 0.02 (<0.01; 0.66) 0.027
PFNA 0.84 Ref 0.86 0.29 (0.05; 1.61) 0.157 0.64 0.02 (<0.01; 0.53) 0.019
PFDA 0.23 Ref 0.29 1.24 (0.26; 5.90) 0.787 0.15 0.05 (<0.01; 0.83) 0.037
PFUnA 0.15 Ref 0.14 0.73 (0.29; 1.85) 0.511 0.12 0.23 (0.05; 1.15) 0.073
PFHxS 1.21 Ref 1.12 0.25 (0.03; 1.82) 0.170 0.89 0.02 (<0.01; 0.53) 0.018
PFOS 3.30 Ref 3.10 0.52 (0.13; 2.09) 0.353 2.35 0.14 (0.01; 1.66) 0.119
sumPFCA 3.96 Ref 4.04 0.49 (0.05; 4.47) 0.527 3.29 0.01 (<0.01; 0.39) 0.015
sumPFSA 4.82 Ref 4.84 0.42 (0.07; 2.57) 0.349 4.58 0.05 (0.00; 1.50) 0.083
aConcentrations of PFAAs (ng/ml) were log-transformed for the multinomial logistic regression analysis that was adjusted for age, sex, BMI, serum lipids and
fasting insulin
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place by dose-dependent induction of CYP1A2 protein
capable of hepatic sequestration of these compounds.
However, as PCB-118 and β-HCH did not correlate with
CYP1A2 expression and did not accumulate to liver in
these studies [16, 43], and as decreased CYP1A2 protein
expression levels were observed in liver microsomes of
patients with NASH [44], possible hepatic accumulation
should take place by other mechanisms. For PFAAs a rat
study showed that multiple proteins in the liver are cap-
able for specific binding to PFOA, but those proteins
were not specified [45]. Unfortunately, from the very
limited amount of liver tissue available it was not pos-
sible to analyse the level of POPs and PFAAs and com-
pare them to the levels in serum.
Regarding excretion, the presence of POPs in human
bile from autopsy samples with significant relationship
to concentrations in blood, adipose fat and liver indi-
cates biliary excretion of POPs [46, 47]. NASH patients
generally have increased levels of bile acids in both
plasma and liver tissue [48, 49] and an increase of serum
bile acids in NASH as compared to less severe stages of
NAFLD has been found in obese patients undergoing
bariatric surgery [50]. In addition, normally a substantial
portion of POPs excreted in bile is reabsorbed by the in-
testine after deconjugation of bile salts by intestinal
microflora [51], but the possibility of impaired entero-
hepatic circulation of bile acids in those with NASH has
been suggested [52]. Thus, increase in biliary elimination
with NAFLD progression could explain the generally in-
verse associations of serum POPs with NASH and liver
inflammation that reached statistical significance for
PCB-118 and β-HCH. Contrary to our results, in former
lindane manufacturers liver disease (elevated AST, ALT
or γ-GT) was positively correlated with longer β-HCH
elimination half-life from blood [53]. However, without
information of NASH status, the relevance of this com-
pared to our findings is unsure.
For PFAAs, the urine was concluded to be the major
elimination route for short chain perfluorinated carboxylic
acids (PFCAs) (C ≤8), but for longer PFCAs, PFOS and
PFHxS other non-specified routes of excretion likely con-
tributed to overall elimination [54]. Thus, it cannot be de-
duced whether increased biliary excretion with NASH
might explain the inverse associations observed between
some PFAAs and lobular inflammation. However, our re-
sults at baseline are generally opposite to epidemiological
and occupational studies where a slight positive associ-
ation between PFOA and liver enzymes (ALT and γ-GT)
in obese subjects was observed [34, 55].
In part of the models the number of covariates included
increased the significance of associations and improved the
precision of effect estimates. Regarding the association of
PCB-118 with diagnosis and steatosisgrade (Table 3 and
Additional file 1: Table S1) serum insulin level was the key
covariate. In addition to a significant difference in the
insulin levels between different diagnosis groups at
Table 5 Associations between ALT and POPs at baseline and at 12 months
Baseline (n = 115)a 12 months (n = 92)b
Compound B (95 % CI) p-value p-interactionc B (95 % CI) p-value p-interactionc
HCB -0.20 (-0.40,0.00) 0.055 0.220 0.09 (-0.09,0.28) 0.309 0.256
β-HCH -0.17 (-0.33,-0.01) 0.035 0.070 0.18 (-0.02,0.39) 0.075 0.017
Trans-nonachlor -0.11 (-0.26,0.04) 0.133 0.310 0.15 (0.00,0.30) 0.055 0.035
p,p′-DDE -0.05 (-0.16,0.07) 0.446 0.759 0.11 (-0.01,0.24) 0.076 0.702
PCB - 118 -0.09 (-0.25,0.07) 0.275 0.414 0.19 (0.02,0.36) 0.032 0.074
PCB - 153 -0.21 (-0.42,-0.01) 0.043 0.567 0.18 (-0.02,0.38) 0.083 0.080
PCB - 138 -0.17 (-0.34,0.00) 0.052 0.576 0.14 (-0.05,0.33) 0.138 0.086
PCB - 156 -0.19 (-0.39,0.01) 0.065 0.683 0.19 (0.00,0.38) 0.047 0.053
PCB - 180 -0.30 (-0.56,-0.04) 0.023 0.832 0.20 (-0.01,0.41) 0.064 0.081
PCB - 170 -0.33 (-0.60,-0.06) 0.019 0.762 0.19 (-0.03,0.42) 0.093 0.093
BDE - 47 0.08 (-0.06,0.22) 0.260 0.866 0.07 (-0.07,0.20) 0.326 0.051
BDE - 153 0.11 (-0.02,0.23) 0.085 0.594 0.15 (0.04,0.26) 0.009 0.508
BDE - 209 -0.01 (-0.10,0.08) 0.801 0.705 0.02 (-0.08,0.11) 0.738 0.210
SumPCBs -0.24 (-0.46,-0.02) 0.033 0.592 0.19 (-0.02,0.39) 0.078 0.071
SumBDEs 0.03 (-0.09,0.14) 0.662 0.580 0.07 (-0.05,0.19) 0.248 0.028
aConcentrations of POPs (ng/g lipids) and ALT were log-transformed for the linear regression analysis at baseline that was adjusted for age, sex, BMI and
fasting insulin
bConcentrations of POPs (ng/g lipids) and ALT were log-transformed for the linear regression analysis at 12 months that was adjusted for age, sex, weight change
and fasting insulin
cp-value for interaction between each POP and sex was tested in a model where the POP*sex interaction term was added as a covariate in addition to other
covariates used at baseline and at 12 months
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baseline (Table 1), insulin also correlated with liver in-
flammation (R2 = 0.207, p = 0.008) and steatosisgrade
(R2 = 0.217, p = 0.006). Similarly, for PFAAs and inflam-
mation (Table 4 and Additional file 2: Table S2), the
most important covariate was serum lipids followed by
serum insulin, sex and BMI. Here, serum lipids correlated
with inflammation (R2 = 0.269, p = 0.001). As insulin, and
possibly also lipids may be a confounders in the models,
related to POPs [32], PFAAs [34] and NAFLD [4], they
can be expected to have an impact on the effect estimates
but less so on their precision. However, the mechanism by
which e.g. impaired insulin sensitivity would change the
distribution of POPs in this population of morbidly obese
is not known.
Change of associations between POPs and ALT from
negative at baseline to positive at 12 months and their
sex specificity was very interesting (Table 5). Positive
POP-ALT associations among women at 12 months
(Additional file 4: Table S4) are in line with other meta-
bolic outcomes. For example, in a 25-year follow-up study
higher baseline PCB serum levels were associated with in-
creased incidence of T2D in women, but not in men [56].
However, because effect estimates were similar among
men for many of the POPs, it is also possible that smaller
number of men may in part be the reason for less signifi-
cant results (Additional file 4: Table S4). The French bar-
iatric surgery cohort observed a positive association
between a diminished improvement of liver markers and
increased plasma POP concentrations after surgery, but
no stratification by sex was performed. This was inter-
preted as the beneficial effects of weight loss possibly be-
ing slowed down or decreased by higher (hepatotoxic)
POP levels [37]. Our results among females at 12 months
can be interpreted similarly. As a whole, at 12 months in-
crease in POP levels plus improvement in the general clin-
ical situation both increase the likelihood of POP-related
ALT signal to be observed if such exists. Also, at
12 months significant clinical differences between baseline
groups of liver phenotype had vanished (Table 1) making
the study material more homogenous and similar to the
general population (NHANES) that showed positive asso-
ciations between liver enzymes and POPs [33].
The mean/median baseline concentrations of most
POPs (especially PCBs) in this study were very similar to
those reported recently in other POPs-bariatric surgery
cohorts from France [37], Belgium [57], Canada [35] and
South-Korea [36]. Although there was a significant in-
crease in POP levels in response obesity surgery for
most compounds, but mean ΔPOPs in our study were
slightly [37] or much lower [35, 57] than those observed in
previous studies 12 months after bariatric surgery. This
can in part be explained by the differences in the BMI de-
creases (ΔBMIs) attained by surgery between studies. Hue
et al. reported that ΔPOPs is not monotonic for
organochlorine POPs, but shows a much faster rate of in-
crease for ΔBMI >14 kg/m2. In his study morbidly obese
subjects who underwent bariatric surgery had at 12 months
ΔBMI 16–26 kg/m2 (n = 8) and a mean ΔPOPs of 390 %
for the sum of plasma organochlorine compounds [35]. In
our total data ΔBMIs and ΔPOPs were more modest; the
95th percentiles were 17.5 kg/m2 for ΔBMI and de-
pending on the compound 150-330 % for ΔPOPs, re-
spectively (Table 2).
To our knowledge no previous study has explored
changes in serum PFAAs concentrations following diet
or bariatric surgery induced weight loss. The known ten-
dency of PFAAs to bind with proteins in blood and espe-
cially in liver [18] rather than in fat was indirectly seen
in the results of this study, where only minor (<7 % for
all studied PFAAs) changes in the median serum con-
centrations following weight loss were observed. Median
baseline PFAAs concentrations in the current study were
lower than those reported e.g. in the general US [34]
and Norway [58] adult population.
Obesity management prior to recruitment was similar
for all patients, i.e. they had non-satisfactory response to
conservative treatment given according to Finnish Current
Care Guidelines (e.g. counselling on diet and physical exer-
cise). Possible weight losses during pre-recruitment period
and pre-surgery low calorie diet period were not recorded.
It can be speculated that patients with a better compliance
to their physician recommendation prior to surgery would
more likely have lost weight which could have led to both
an increase in POP levels in blood and an improvement in
liver lobular inflammation. Our results at baseline reflect
cross-sectional situation on the day of surgery.
This study has several limitations. First, the number of
subjects was limited in each class liver phenotype class.
However, clear characterization in different liver pheno-
types gave a possibility to compare normal liver to stea-
tosis and NASH. Second, there is a risk of false findings
due to multiple testing. Third, analysis of POPs from
liver biopsies would have been extremely valuable add-
itional information, but it was not possible due to very
limited amount of tissue available. Fourth, follow-up
liver biopsies at 12 months would also have been valu-
able, but receiving they are hard to justify ethically. Fifth,
study was cross-sectional in nature and the causality for
the main findings cannot be established.
Conclusions
Using a special cohort of obese individuals with high risk
of NASH that underwent bariatric surgery we found a
negative association between serum concentrations of
PCB-118, β-HCH and several PFAAs with lobular in-
flammation at baseline. Reason for this is unclear, but in-
crease in biliary elimination with NASH could be proposed
as one explanation especially for POPs. ALT had significant
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or nearly significant negative associations with most POPs
at baseline that turned positive at 12 months after major
improvements in clinical status. There was an interaction
between some POPs and sex at 12 months, and in stratified
data positive associations were observed mainly in females
but not in males. Our results at 12 months agree with the
associations observed previously between POPs and in-
creased ALT, used as surrogate for liver disease.
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